-
Pulmatrix's COPD Candidate Shows Early Safety, Preliminary Pharmacokinetic Results
Monday, March 21, 2022 - 12:33pm | 217Read More...Pulmatrix Inc (NASDAQ: PULM) announced topline results of its recently completed Phase 1b clinical study of PUR1800 in patients with stable Chronic Obstructive Pulmonary Disease (COPD). PUR1800 is a narrow spectrum kinase inhibitor (NSKI) administered as a dry powder for inhalation...
-
Verona Pharma's pMDI Ensifentrine Shows Improved Lung Function In Mid-Stage COPD Study
Tuesday, February 2, 2021 - 6:11am | 232Read More...Verona Pharma PLC (NASDAQ: VRNA) has reported positive data from the Phase 2 study evaluating pressurized metered-dose inhaler formulation (pMDI) of ensifentrine in moderate to severe chronic obstructive pulmonary disease. The study met all primary and secondary endpoints...
